Background
Methods
Clinical characteristics
Treatment (n = 57) | Controls (n = 45) |
P
| |
---|---|---|---|
Sex | >0.05 | ||
Male | 37 | 27 | |
Female | 20 | 18 | |
Age | >0.05 | ||
Mean | 64 | 64 | |
Range | 52–75 | 47–79 | |
Implanted seeds by bronchoscopy | – | ||
Total | 399 | – | |
Mean | 7 | – | |
Range | 5–10 | – | |
Implanted seeds using CT | – | ||
Total | 399 | – | |
Mean | 33 | – | |
Range | 20–46 | – | |
Chemotherapy, n (%) | 57 (100.0) | 45 (100.0) | – |
Serious complications, n (%) | 0 | 0 | – |
Mild complications, n (%) | – | – | |
Slight hemoptysis | 3 (5.3) | ||
Decreased WBC | 4 (7.0) | ||
Pneumothorax, low fever, particle shifting, and mild pulmonary fibrosis | 2 (3.5) | ||
Pneumothorax, bleeding, and mild adverse radiation reaction | 1 (1.8) |
Equipment
Operation procedures
Criteria for effectiveness evaluation
Statistical analysis
Results
Clinical outcomes
Survival
Groups | Patients (n) | Survival time (months) |
---|---|---|
Treatment | 57 | 11.13 ± 2.08* |
Controls | 45 | 4.57 ± 2.05 |
Groups | Patients (n) | Rate of airway cross-section stenosis | Dyspnea index |
---|---|---|---|
Treatment | 57 | ||
Before treatment | 6.86 ± 1.68 | 12.73 ± 2.14 | |
After treatment | 2.57 ± 4.43* | 5.25 ± 3.44* | |
Controls | 45 | ||
Before treatment | 5.57 ± 2.07 | 11.84 ± 2.65 | |
After treatment | 6.29 ± 4.43 | 15.71 ± 4.02 |
Quality of life
Groups | Patients (n) | EORQLQ-LCl3 | Physiological functions | Clinicians and disease | Emotions and social and family situations | Overall quality of life |
---|---|---|---|---|---|---|
Treatment | ||||||
Before treatment | 57 | 21.18 ± 2.63 | 15.41 ± 2.28 | 19.15 ± 2.39 | 24.13 ± 3.91 | 98.87 ± 5.37 |
After treatment | 57 | 25.39 ± 3.76* | 17.89 ± 3.01* | 25.64 ± 3.12* | 39.26 ± 3.42* | 125.38 ± 6.37* |
Controls | ||||||
Before treatment | 45 | 20.67 ± 2.97 | 15.68 ± 2.37 | 19.86 ± 2.54 | 23.42 ± 3.87 | 98.18 ± 6.89 |
After treatment | 45 | 14.32 ± 3.96 | 11.29 ± 2.57 | 13.41 ± 2.32 | 20.12 ± 2.87 | 87.13 ± 4.52 |